Principles Alcohol & Drug Recovery Program

Durect Corporation is a late-stage biopharmaceutical company based in Vacaville, CA, that specializes in epigenetic modulation to develop innovative therapies for serious and life-threatening conditions, including acute organ injury and cancer. Their unique approach targets dysregulated DNA methylation to address the underlying pathophysiology and improve cellular function or suppress tumor growth, with the potential to revolutionize medicine and improve patients' lives. One of their key focuses is on alcohol-associated hepatitis (AH), a severe form of liver disease that accounts for a significant number of hospitalizations in the U.S. each year. Durect's first epigenetic modulator, larsucosterol, has shown promising outcomes in clinical trials and may become a new standard of care for AH patients. They are currently conducting a Phase 2b study, AHFIRM, in multiple clinical trial sites across the U.S., EU, U.K., and Australia. Durect Corporation welcomes strategic partnerships to further advance their mission of making a meaningful impact on patients' lives and offering better therapeutic options.Generated from the website

From the website:Breakthrough science. One moment, one day, one person at a time.